Singapore, Singapore

Runyi Adeline Lam

USPTO Granted Patents = 2 

Average Co-Inventor Count = 17.0

ph-index = 1


Company Filing History:


Years Active: 2023-2024

Loading Chart...
2 patents (USPTO):

Title: Runyi Adeline Lam: Innovator in Bispecific Antibodies

Introduction

Runyi Adeline Lam is a prominent inventor based in Singapore, known for her significant contributions to the field of biomedicine. She has been instrumental in developing innovative solutions aimed at treating various diseases through her research and inventions. With a total of two patents to her name, she continues to push the boundaries of medical science.

Latest Patents

Runyi Adeline Lam's latest patents focus on bispecific anti-CCL2 antibodies. These antibodies are designed to bind to two different epitopes on human CCL2. The inventions include pharmaceutical compositions that can be manufactured and utilized as medicaments for the treatment of cancers, inflammatory, autoimmune, and ophthalmologic diseases. Her work in this area represents a significant advancement in therapeutic options for patients suffering from these conditions.

Career Highlights

Runyi Adeline Lam is currently associated with Hoffmann-La Roche Inc., where she applies her expertise in antibody development. Her role at the company allows her to collaborate with other leading scientists and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Some of her notable coworkers include Jens Fischer and Guy Georges. Their collaboration enhances the research environment and fosters innovation in the projects they undertake together.

Conclusion

Runyi Adeline Lam is a trailblazer in the field of biomedicine, with her innovative patents paving the way for new treatments. Her dedication to research and collaboration with esteemed colleagues underscores her commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…